Skip to main content
. Author manuscript; available in PMC: 2010 Oct 5.
Published in final edited form as: Oncotarget. 2010 May 1;1(1):22–33. doi: 10.18632/oncotarget.105

Fig. 6. Combinations of STAT3 and MEK inhibitors induced synergistic cytotoxicities on CKS1B-transfected myeloma cells.

Fig. 6

(A) Cell growth and (B) cell death were evaluated in CKS1B-transfected OCI-MY5 treated with MEK1 inhibitorU0126 (10 μM) plus STAT3 inhibitor Nifuroxazide (10 nM) (N+U Inh) and Nifuroxazide plus BCL2 inhibitor (10 nM) (N+B Inh) for 24 hours. The total cell numbers and cell viability between empty vector (EV) vs. CKS1B-cDNA transfected OCI-MY5 cell line are 4.85M vs. 5.11M and 92% vs. 90% in DMSO, 3.10M vs. 1.61M and 61% vs. 35% in Nif, 3.46M vs. 2.10M and 78% vs. 53% in U0126, 2.87M vs. 0.85M and 64% vs. 32% in BCL2 Inh, 0.90M vs. 0.17M and 39% vs. 14% in N + U, and 0.36M vs. 0.07M and 29% vs. 11% in N + B, respectively. (C) Cell growth and (D) cell death were evaluated in CKS1B-transfected XG1 treated with N+U Inh and N+B Inh for 24 hours. The total cell numbers and cell viability between empty vector (EV) vs. CKS1B-cDNA transfected XG1 cell line are 4.12M vs. 4.30M and 90% vs. 92% in DMSO, 2.17M vs. 1.64M and 62% vs. 35% in Nif, 2.63M vs. 1.83M and 78% vs. 52% in U0126, 2.03M vs. 0.96M and 65% vs. 32% in BCL2 Inh, 0.97M vs. 0.20M and 33% vs. 2% in N + U, and 0.58M vs. 0.09M and 27% vs. 3% in N + B, respectively. The Combination Indices values of EV-and CKS1B -transfected OCI-MY5 and XG-1 cells treated with combination of STAT3 and MEK1 inhibitors are 0.44 and 0.30, and 0.69 and 0.27, respectively; while these cells treated with combination of STAT3 and BCL2 inhibitors are 0.37 and 0.27, and 0.50 and 0.26, respectively. Both combinations showed synergistic effects in inhibition MM cell growth and induction MM cell apoptosis. Untreated cells and EV-transfected cells with or without treatment served as controls. Results were expressed as Mean ± SD of three independent experiments ( *p < 0.05 and **p < 0.01).